2006
Plasminogen activator inhibitor-1 deficiency protects against aldosterone-induced glomerular injury
Ma J, Weisberg A, Griffin JP, Vaughan DE, Fogo AB, Brown NJ. Plasminogen activator inhibitor-1 deficiency protects against aldosterone-induced glomerular injury. Kidney International 2006, 69: 1064-1072. PMID: 16528256, DOI: 10.1038/sj.ki.5000201.Peer-Reviewed Original ResearchMeSH KeywordsAlbuminuriaAldosteroneAnimalsBlood PressureChemokine CCL2CollagenFibronectinsGene ExpressionGlomerulonephritisHemodynamicsKidney GlomerulusMacrophagesMaleMiceMice, Inbred C57BLMice, Inbred StrainsMyocardiumNephrectomyOsteopontinPlasminogen Activator Inhibitor 1RNA, MessengerSialoglycoproteinsSodiumConceptsMonocyte chemoattractant protein-1Plasminogen activator inhibitor-1WT miceGlomerular injuryPlasminogen activator inhibitor-1 deficiencyCollagen IIIMRNA expressionPAI-1-deficient miceRenal collagen contentRenal osteopontin expressionSodium/potassium ratioUrine albumin excretionSystolic blood pressureRenal mRNA expressionChemoattractant protein-1Activator inhibitor-1Collagen IGrowth factor betaAlbumin excretionSodium excretionBlood pressureMesangial expansionRenal expressionCardiac injuryUrine volume
2005
Regression of Existing Glomerulosclerosis by Inhibition of Aldosterone
Aldigier JC, Kanjanbuch T, Ma LJ, Brown NJ, Fogo AB. Regression of Existing Glomerulosclerosis by Inhibition of Aldosterone. Journal Of The American Society Of Nephrology 2005, 16: 3306-3314. PMID: 16192423, DOI: 10.1681/asn.2004090804.Peer-Reviewed Original ResearchConceptsInhibition of aldosteroneAngiotensin type 1 receptor antagonistType 1 receptor antagonistAdult male Sprague-DawleySeverity of glomerulosclerosisDevelopment of glomerulosclerosisMale Sprague-DawleyEffect of inhibitionCONT ratsGlomerulosclerosis indexSerum creatinineSystolic BPAntihypertensive drugsReceptor antagonistSprague-DawleySP ratsGlomerulosclerosisSpironolactoneSame ratsRatsSP groupAldosteroneFurther treatmentWkInhibition
2004
Pharmacological Inhibition and Genetic Deficiency of Plasminogen Activator Inhibitor-1 Attenuates Angiotensin II/Salt-Induced Aortic Remodeling
Weisberg AD, Albornoz F, Griffin JP, Crandall DL, Elokdah H, Fogo AB, Vaughan DE, Brown NJ. Pharmacological Inhibition and Genetic Deficiency of Plasminogen Activator Inhibitor-1 Attenuates Angiotensin II/Salt-Induced Aortic Remodeling. Arteriosclerosis Thrombosis And Vascular Biology 2004, 25: 365-371. PMID: 15576638, DOI: 10.1161/01.atv.0000152356.85791.52.Peer-Reviewed Original ResearchMeSH KeywordsAcetatesAdministration, OralAngiotensin IIAnimalsAntigens, DifferentiationAortaAortic DiseasesBlood PressureChemokine CCL2Collagen Type ICollagen Type IIIDrug Evaluation, PreclinicalFibronectinsFibrosisGene Expression RegulationGlomerulosclerosis, Focal SegmentalHeartHypertrophy, Left VentricularIndoleacetic AcidsIndolesKidneyMaleMiceMice, Inbred C57BLMice, KnockoutMyocardiumNephrectomyOsteopontinPlasminogen Activator Inhibitor 1Random AllocationRNA, MessengerSialoglycoproteinsSingle-Blind MethodSodium Chloride, DietaryConceptsAng IIAortic remodelingCardiac fibrosisPAI-039PAI-1 inhibitionVascular remodelingCardiac hypertrophyMouse modelHeart/body weight ratioAng II/saltWall thickeningPharmacological inhibitionSmall molecule PAI-1 inhibitorAortic mRNA expressionHigh salt intakeAortic wall thickeningMale C57BL/6J miceBody weight ratioChemoattractant protein-1PAI-1 deficiencyPAI-1 activityPAI-1 inhibitorPlasminogen activator inhibitorPressor responseAngiotensin II